Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas.
Lung Cancer
; 102: 42-43, 2016 12.
Article
en En
| MEDLINE
| ID: mdl-27987587
ABSTRACT
Non-small cell lung cancers (NSCLCs) have molecular characterization and most druggable genetic and molecular abnormalities, such as EGFR, ERBB2 and BRAF mutations, and ALK and ROS1 rearrangements, have been observed in a subset of adenocarcinomas or large cell carcinomas [1]. Even if these abnormalities are seldom detected in squamous cell carcinomas (SQCC), some rare cases of SQCC have been reported to harbor EGFR, ROS1 or ALK genetic alterations with in some cases a response to targeted therapies [2,3]. Here, we describe a patient with a SQCC harboring ROS1 rearrangement and a response to the target therapy, crizotinib.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Pirazoles
/
Piridinas
/
Proteínas Tirosina Quinasas
/
Carcinoma de Células Escamosas
/
Proteínas Proto-Oncogénicas
/
Inhibidores de Proteínas Quinasas
/
Neoplasias Pulmonares
Tipo de estudio:
Diagnostic_studies
Límite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Lung Cancer
Asunto de la revista:
NEOPLASIAS
Año:
2016
Tipo del documento:
Article